0	13	Transcription	transcription	NN
14	21	factors	factor	NNS
22	24	as	as	IN
25	32	targets	target	NNS
33	36	for	for	IN
37	46	oxidative	oxidative	JJ
47	57	signalling	signalling	NN
58	64	during	during	IN
65	75	lymphocyte	lymphocyte	NN
76	86	activation	activation	NN
86	87	.	.	.

89	91	We	we	PRP
92	102	previously	previously	RB
103	107	have	have	VBP
108	120	demonstrated	demonstrate	VBN
121	122	a	a	DT
123	134	requirement	requirement	NN
135	138	for	for	IN
139	148	oxidative	oxidative	JJ
149	155	events	event	NNS
156	162	during	during	IN
163	167	cell	cell	NN
168	173	cycle	cycle	NN
174	179	entry	entry	NN
180	182	in	in	IN
183	184	T	t	NN
185	196	lymphocytes	lymphocyte	NNS
197	200	and	and	CC
201	205	have	have	VBP
206	218	hypothesised	hypothesise	VBN
219	223	that	that	IN
224	232	reactive	reactive	JJ
233	239	oxygen	oxygen	NN
240	247	species	specie	NNS
248	251	may	may	MD
252	255	act	act	VB
256	258	as	as	IN
259	272	intracellular	intracellular	JJ
273	283	signalling	signalling	NN
284	290	agents	agent	NNS
291	297	during	during	IN
298	308	lymphocyte	lymphocyte	NN
309	319	activation	activation	NN
319	320	.	.	.

321	323	In	in	IN
324	327	the	the	DT
328	335	current	current	JJ
336	341	study	study	NN
341	342	,	,	,
343	353	cysteamine	cysteamine	NN
353	354	,	,	,
355	357	an	an	DT
358	368	aminothiol	aminothiol	NN
369	377	compound	compound	NN
378	382	with	with	IN
383	394	antioxidant	antioxidant	JJ
395	403	activity	activity	NN
403	404	,	,	,
405	408	has	have	VBZ
409	413	been	be	VBN
414	418	used	use	VBN
419	421	to	to	TO
422	429	further	further	RB
430	441	investigate	investigate	VB
442	445	the	the	DT
446	450	role	role	NN
451	453	of	of	IN
454	463	oxidative	oxidative	JJ
464	474	signalling	signalling	NN
475	481	during	during	IN
482	492	lymphocyte	lymphocyte	NN
493	503	activation	activation	NN
503	504	.	.	.

505	514	Treatment	Treatment	NNP
515	517	of	of	IN
518	524	normal	normal	JJ
525	530	human	human	JJ
531	541	peripheral	peripheral	JJ
542	547	blood	blood	NN
548	559	lymphocytes	lymphocyte	NNS
560	564	with	with	IN
565	575	cysteamine	cysteamine	NN
576	578	in	in	FW
579	584	vitro	vitro	FW
585	588	was	be	VBD
589	594	found	find	VBN
595	597	to	to	TO
598	605	inhibit	inhibit	VB
606	619	proliferation	proliferation	NN
620	622	in	in	IN
623	624	a	a	DT
625	639	dose-dependent	dose-dependent	JJ
640	646	manner	manner	NN
646	647	,	,	,
648	652	with	with	IN
653	664	essentially	essentially	RB
665	673	complete	complete	JJ
674	684	inhibition	inhibition	NN
685	694	occurring	occur	VBG
695	697	at	at	IN
698	699	a	a	DT
700	704	dose	dose	NN
705	707	of	of	IN
708	711	400	400	CD
712	718	microM	microm	NN
718	719	.	.	.

720	724	This	this	DT
725	735	inhibitory	inhibitory	JJ
736	742	effect	effect	NN
743	746	was	be	VBD
747	754	limited	limit	VBN
755	757	to	to	TO
758	761	the	the	DT
762	767	first	first	JJ
768	769	2	2	CD
770	771	h	h	NN
772	777	after	after	IN
778	787	mitogenic	mitogenic	JJ
788	798	activation	activation	NN
798	799	,	,	,
800	810	localizing	localize	VBG
811	814	the	the	DT
815	825	time-frame	time-frame	NN
826	828	of	of	IN
829	835	action	action	NN
836	838	of	of	IN
839	849	cysteamine	cysteamine	NN
850	852	to	to	TO
853	859	within	within	IN
860	863	the	the	DT
864	874	commitment	commitment	NN
875	881	period	period	NN
881	882	.	.	.

883	885	It	it	PRP
886	895	therefore	therefore	RB
896	899	was	be	VBD
900	902	of	of	IN
903	911	interest	interest	NN
912	914	to	to	TO
915	924	establish	establish	VB
925	930	which	which	WDT
930	931	,	,	,
932	934	if	if	IN
935	938	any	any	DT
938	939	,	,	,
940	950	commitment	commitment	NN
951	957	events	event	NNS
958	962	were	be	VBD
963	971	affected	affect	VBN
972	974	by	by	IN
975	984	oxidative	oxidative	JJ
985	995	signalling	signalling	NN
996	1002	during	during	IN
1003	1007	cell	cell	NN
1008	1013	cycle	cycle	NN
1014	1019	entry	entry	NN
1019	1020	.	.	.

1021	1027	Taking	take	VBG
1028	1031	the	the	DT
1032	1036	IL-2	il-2	NN
1037	1041	gene	gene	NN
1042	1044	as	as	IN
1045	1046	a	a	DT
1047	1056	candidate	candidate	NN
1056	1057	,	,	,
1058	1060	we	we	PRP
1061	1069	examined	examine	VBD
1070	1073	the	the	DT
1074	1080	effect	effect	NN
1081	1083	of	of	IN
1084	1094	cysteamine	cysteamine	NN
1095	1104	treatment	treatment	NN
1105	1107	on	on	IN
1108	1113	early	early	JJ
1114	1118	gene	gene	NN
1119	1129	expression	expression	NN
1130	1136	during	during	IN
1137	1147	lymphocyte	lymphocyte	NN
1148	1158	activation	activation	NN
1158	1159	,	,	,
1160	1163	and	and	CC
1164	1166	on	on	IN
1167	1170	the	the	DT
1171	1179	activity	activity	NN
1180	1182	of	of	IN
1183	1196	transcription	transcription	NN
1197	1204	factors	factor	NNS
1205	1209	AP-1	ap-1	NN
1209	1210	,	,	,
1211	1219	NF-kappa	NF-kappa	NNP
1220	1221	B	B	NNP
1221	1222	,	,	,
1223	1228	NF-AT	NF-AT	NNP
1229	1232	and	and	CC
1233	1237	Oct1	Oct1	NNP
1237	1238	,	,	,
1239	1244	whose	whose	WP$
1245	1254	functions	function	NNS
1255	1258	are	be	VBP
1259	1267	required	require	VBN
1268	1271	for	for	IN
1272	1282	expression	expression	NN
1283	1285	of	of	IN
1286	1289	the	the	DT
1290	1294	IL-2	il-2	NN
1295	1299	mRNA	mrna	NN
1299	1300	.	.	.

1301	1311	Cysteamine	Cysteamine	NNP
1312	1321	treatment	treatment	NN
1322	1331	inhibited	inhibit	VBD
1332	1336	both	both	CC
1337	1347	expression	expression	NN
1348	1350	of	of	IN
1351	1354	the	the	DT
1355	1359	IL-2	il-2	NN
1360	1364	mRNA	mrna	NN
1365	1368	and	and	CC
1369	1378	secretion	secretion	NN
1379	1381	of	of	IN
1382	1386	IL-2	il-2	NN
1387	1391	into	into	IN
1392	1395	the	the	DT
1396	1403	culture	culture	NN
1404	1410	medium	medium	NN
1410	1411	.	.	.

1412	1415	The	the	DT
1416	1426	inhibitory	inhibitory	JJ
1427	1433	effect	effect	NN
1434	1436	of	of	IN
1437	1447	cysteamine	cysteamine	NN
1448	1451	may	may	MD
1452	1454	be	be	VB
1455	1463	mediated	mediate	VBN
1464	1466	at	at	IN
1467	1472	least	least	JJS
1473	1475	in	in	IN
1476	1480	part	part	NN
1481	1483	by	by	IN
1484	1486	an	an	DT
1487	1493	effect	effect	NN
1494	1496	on	on	IN
1497	1510	transcription	transcription	NN
1511	1517	factor	factor	NN
1518	1526	function	function	NN
1526	1527	,	,	,
1528	1530	as	as	IN
1531	1534	the	the	DT
1535	1538	DNA	dna	NN
1539	1546	binding	binding	NN
1547	1557	activities	activity	NNS
1558	1560	of	of	IN
1561	1565	AP-1	AP-1	NNP
1566	1569	and	and	CC
1570	1578	NF-kappa	NF-kappa	NNP
1579	1580	B	B	NNP
1581	1590	extracted	extract	VBN
1591	1595	from	from	IN
1596	1614	mitogen-stimulated	mitogen-stimulated	JJ
1615	1620	cells	cell	NNS
1621	1625	were	be	VBD
1626	1639	significantly	significantly	RB
1640	1649	inhibited	inhibit	VBN
1650	1652	by	by	IN
1653	1663	cysteamine	cysteamine	NN
1664	1673	treatment	treatment	NN
1673	1674	.	.	.

1675	1688	Interestingly	interestingly	RB
1688	1689	,	,	,
1690	1694	Oct1	Oct1	NNP
1695	1698	and	and	CC
1699	1704	NF-AT	NF-AT	NNP
1705	1708	DNA	DNA	NNP
1709	1716	binding	binding	NN
1717	1725	activity	activity	NN
1726	1730	were	be	VBD
1731	1734	not	not	RB
1735	1743	affected	affect	VBN
1744	1746	by	by	IN
1747	1757	cysteamine	cysteamine	NN
1758	1767	treatment	treatment	NN
1767	1768	,	,	,
1769	1779	suggesting	suggest	VBG
1780	1784	that	that	IN
1785	1794	oxidative	oxidative	JJ
1795	1805	signalling	signalling	NN
1806	1815	processes	process	NNS
1816	1823	operate	operate	VBP
1824	1826	in	in	IN
1827	1828	a	a	DT
1829	1838	selective	selective	JJ
1839	1845	manner	manner	NN
1845	1846	.	.	.

1847	1850	The	the	DT
1851	1865	identification	identification	NN
1866	1868	of	of	IN
1869	1879	regulatory	regulatory	JJ
1880	1888	proteins	protein	NNS
1888	1889	,	,	,
1890	1894	such	such	JJ
1895	1897	as	as	IN
1898	1911	transcription	transcription	NN
1912	1919	factors	factor	NNS
1919	1920	,	,	,
1921	1923	as	as	IN
1924	1933	molecular	molecular	JJ
1934	1941	targets	target	NNS
1942	1945	for	for	IN
1946	1955	oxidative	oxidative	JJ
1956	1966	signalling	signalling	NN
1967	1975	provides	provide	VBZ
1976	1983	further	further	JJ
1984	1992	evidence	evidence	NN
1993	1995	to	to	TO
1996	2005	implicate	implicate	VB
2006	2015	oxidative	oxidative	JJ
2016	2026	signalling	signalling	NN
2027	2029	as	as	IN
2030	2035	being	be	VBG
2036	2046	intimately	intimately	RB
2047	2055	involved	involve	VBN
2056	2058	in	in	IN
2059	2062	the	the	DT
2063	2065	G0	g0	NN
2066	2068	to	to	TO
2069	2071	G1	g1	NN
2072	2077	phase	phase	NN
2078	2088	transition	transition	NN
2089	2091	in	in	IN
2092	2093	T	t	NN
2094	2105	lymphocytes	lymphocyte	NNS
2105	2106	.	.	.